Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.

Biotecnología

Ms. Rebecca Lynn Hudson C.A., C.P.A., CA, CPA

Chief Financial Officer

Mr. William  Rascan

Pres, Chief Executive Officer & Director

Ms. Rebecca Lynn Hudson C.A., CPA, CA, CPA

Ms. Jacqueline  McConnell

Chief Operating Officer & Director

Dr. Stephen  Glazer

Chief Science Officer & Director

Mr. Derek Lloyd Harry Ivany

Executive Chairman

Dr. Aylia  Mohammadi B.Sc., M.Sc., Ph.D.

Pres & Chief Scientific Officer of Nova Mentis Biotech Corporation

Ms. Kelly  Pladson

Corporation Sec.

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M
Immuron Limited	0M
Aptevo Therapeutics Inc.	0M

Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. Lista de competidores

Principales competidores